Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.

Inclusion Criteria: * Patients who have granted the IC and who are going to comply with the study visits and procedures according to their life expectations. * Patient ≥ 18 years of age * Having a first episode of DCI and presenting an estimated recurrence risk greater than 35%. Exclusion Criteria: * Patients \<18 years old * Pregnant or lactating women * Women of childbearing age who are not willing to use an appropriate contraceptive method (such as oral contraceptives, intrauterine device or contraceptive barrier method along with spermicide or surgical sterilization) during the study. * Life expectancy less than 6 months * Impossibility or serious difficulties of clinical follow-up * Any digestive disease that, at the discretion of the researcher, makes it difficult to assess the response due to impaired bowel habits. * Immunoglobulin treatment in the last 3 months * Previous treatment with Bezlotoxumab * Treatment with an experimental drug in the previous 30 days or participating or planning to participate in any other clinical trial with an experimental drug during the 12-week trial period. * Anti- ICD treatment forecast for more than 14 days (eg vancomycin in descending pattern) for the current episode. * Health center staff * Direct family members of the research team